Autolus Therapeutics plc (AUTL)
$1.81+2.26%Close
SELLRECOVERY · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $482M
- Beta
- 2.14
- P/E (TTM)
- -1.69
- Short % float
- 3.49%
- Days to cover
- 5.7
- SI change
- +0.9%
- 1W
- +1.69%
- 1M
- -7.65%
- vs SPY 1W
- +0.53%
- vs SPY 1M
- -10.65%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AUTL?
- LOPJLB’s latest quantitative signal on Autolus Therapeutics plc (AUTL) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AUTL in?
- Autolus Therapeutics plc (AUTL) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Autolus Therapeutics plc (AUTL) do?
- Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL).…